Recent

% | $
Quotes you view appear here for quick access.

Arrowhead Research Corp. Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • rnai_inv rnai_inv Jan 20, 2012 11:46 AM Flag

    Alnylam to lay off one third of workers

    Biggest company in rnai with lots of cash says: we are cutting costs as much as possible to focus on just 2 core products and will try to partner alsmost everything else we have. What does this say about possibilities of raising cash, favorable upfront payments etc?

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Seems to me that the Anylyn CEO realizes the siRNA cookie tray isn't going to be passed around any again time soon. To that end he switching from a pie in the sky to a show me the money strategy. It wouldn't surprise me if he took some of the $250MM and purchased a more conventional drug in later stage trials. If you followed Millenium's history were in the same boat(different technology) and did just that. MLNM was sold for $8BB mostly because of the purchased technology.

      ARWR isn't quite in the same place. They have such a low market cap that if they can produce an steady income stream of say $5MM/yr from any of the several technologies they've liscensed, that should be enough to get lift off(in my opinion)...providing it's before they run out of cash.

 
ARWR
5.92-0.06(-1.00%)1:32 PMEDT